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ABSTRACT
Objectives: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes 
and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin 
derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET 
and ARID1A are also related to prognosis in endometrial cancer.
Material and methods: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of 
NESF1, MLH1, MSH2,c-MET and ARID1A were examined. 
Results: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of 
NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. 
A significantly lower expression of MLH1 was demonstrated in type I EC. 
Conclusions: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency 
was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.
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INTRODUCTION
Endometrial cancer (EC) is the most commonly occur-
ring gynaecological malignancy in economically developed 
countries. In Europe, the incidence rate amounts to 13.6 per 
100.000 women. In many European countries an increased 
incidence of this tumor has been noted since 2005 [1–3]. 
In over 90% of EC cases, the cancer develops after the age 
of 50, with a median age of 63; in 10–15% it is diagnosed 
before the age of 45 [2, 4].
Bokhman’s hypothesis led to the identification of 
two types of EC differing in etiology, biology and clinical 
course [5].
Type I EC (endometrioid adenocarcinoma) involves 80% 
of all EC cases. In most cases it is sporadic and linked to 
unbalanced estrogen stimulation and metabolic syndrome. 
This EC type manifests slow clinical course and positive 
prognosis. This type of cancer contains mutations in the 
PTEN, KRAS, CTNNB1, P1K3CA genes and in mismatch repair 
(MMR) genes, typical for Lynch syndrome [2, 6–8].
Type II EC (non-endometrioid adenocarcinoma) histologi-
cally encompasses serous, clear cell, poorly differentiated 
cancers of aggressive biology and an unfavorable clinical 
course. They contain mutations in TP53, HER2-neu and BRCA 
[2, 9, 10–12]. 
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Type I EC with a high histological grade (G3) manifests 
a similarly poor prognosis to uterine serous carcinoma (USC), 
belonging to type II [ 6, 3, 13, 14], some well-differentiated, 
early diagnosed endometrioid EC gives recurrent disease, 
which suggests that the traditional Bokman's division may 
not be up to date.
Recent results have shown that more EC types exist. The 
heterogeneity of ECs has been proven by genomic analysis of 
endometrioid and serous cancers. The Cancer Genome Atlas 
(TCGA) developed in 2013, indicates there are 4 types of ECs [15]:
 Ū unique nucleotides spectrum ultra-mutated tumors 
(POLE) — associated with favourable outcome,
 Ū highly-mutated with microsatellite instability, mostly 
with MLH1 promoter methylation,
 Ū a group of low frequency of mutations with low gene 
copy numbers,
 Ū a group with high gene copy numbers and a low fre-
quency of mutations, mainly serous cancers, connected 
to a poor prognosis.
It is suggested that the Genomic Atlas classification 
(TGGA) should be linked to the histological classification of 
ECs, particularly ECs of poor differentiation [16].
The acknowledged and recognized factors which affect the 
clinical course and type of oncological treatment of EC include 
the histological type, grading (G) and clinical stage of disease. 
However, these traditional prognostic factors do not allow 
for tailoring of treatment to individual patients which could 
spare many side effects for over-treated women and reduce 
the number of recurrences in under-treated patient groups. 
Molecular studies also indicate the relationship between 
EC clinical course and several molecular variables, such as: 
condition of hormonal receptors (ER, PR), ARID1A and c-MET 
linked to poor prognosis, metastases and mutations in MMR 
genes detected in Lynch syndrome [17–21]. Recent published 
studies indicated a relationship between Nesfatin-1 (NESF-1) 
with its precursor, NUCB2-nucleobindin 2, and the clinical 
course of EC [22, 23]. NESF-1 is associated with obesity and 
diabetes type II (main risk factors for EC) and participates in 
the regulation of hunger and fat storage, it is associated with 
insulin resistance and glucose homeostasis. 
The aim of this study was to estimate the expression 
of NESF-1, MLH1 and MLH2 belonging to MMR, c-MET and 
ARID1A in two types of endometrial cancer and determine 
relationships between the mentioned factors.
MATERIAL AND METHODS
This was a multi-centre, retrospective study. The investi-
gated material involved archival, histological preparations, 
obtained from uterine endometrial cancer samples taken from 
patients primarily treated surgically between 2007–2014.
All 146 patients included in this retrospective study were 
monitored for the entire five to eight-year period from diag-
nosis of EC through the duration of their treatment and subse-
quent observation. In order to fulfil the selection criteria for the 
study, patients must have been diagnosed at one of the centres 
participating in the study. Only patients where information on 
FIGO grading and histology were complete, who underwent 
treatment for EC at the centre where they were originally di-
agnosed and then monitored for the stated study period by 
practitioners at that specific centre were included in this study.
Out of a total of 146 patients, 38 (26%) patients were 
diagnosed at stage IA according to FIGO, 36 patients (24.7%) 
at stage IB, 37 patients (25.4%) at stage II, 22 (15%) at stage 
III and 13 (8.9%) at stage IV.
In the studied group, 115 patients were diagnosed with 
type I EC (78.8%), in 31 type II EC (21.2%) was detected, this 
included 18 serous types (12.3%), 11 clear cell types and 
2 mucinous types (1.4%).
In 38 patients (25%), endometrial cancer manifested 
a high histological maturity (G1), in 59 patients (38.8%) it 
displayed an intermediate histological differentiation (G2) 
while in 55 patients (36.2%) undifferentiated tumors were 
identified (G3) (Tab. 1).
Table 1. Clinicopathologic characteristics of studied patients with 
endometrial carcinoma
Clinical Staging acc. to FIGO Number of patients 
Endometrioid adenocarcinoma (n = 115)
IA 33
IB 32
II 27
III 14
IV 9
Serous adenocarcinoma G3 (n = 18)
IA 4
IB 3
II 7
III 4
Clear cell adenocarcinoma G3 (n = 11)
IA 1
IB 1
II 2
III 4
IV 3
Mucinous adenocarcinoma (n = 2)
II 1
IV 1
Grading Number of patients 
Endometrioid adenocarcinoma (n = 115)
G1 36
G2 56
G3 23
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Statistical calculations were made using the Mann-Whit-
ney, Kruskall-Wallis and Spearman’s tests (STATISTICA Stat-
Soft Inc, USA). Statistical significance was concluded when 
p was less than 0.05.
RESULTS
A high expression of NESF-1, MLH1, MSH2, c-MET and 
ARID1A was detected, respectively, in 53.1%, 57.7%, 47.3%, 
88.7% and 48.2% patients with endometrial cancer.
The immunohistochemical reaction with antibodies 
against NESF-1 and c-MET was seen in the cytoplasm; MLH1, 
MSH2 and ARID1A manifested nuclear localization.
Histopathological type
In respect to histopathological diagnosis the patients 
formed two groups: endometrioid type (n = 115) and 
non-endometrioid type (n = 31), which included patients 
with serous, clear cell and mucinous cancers.
Positive expression of nesfatin was determined in 
50.99% of patients with type EC I and in 61.3% of patients 
with type II EC. No significant difference was disclosed be-
tween the groups (p = 0.410). MLH1 expression was statisti-
cally lower in type EC I in comparison to type II EC (51.9% vs 
77.4%, p = 0.013). No significant difference was disclosed 
in the expression of MSH2, c-MET and ARIDIA between the 
two subgroups (p < 0.05) (Fig.1).
Clinical stage according to FIGO
Patients with endometrial cancer were subdivided de-
pending on clinical stage into early stage (IA) and later stage 
of the disease (IB–IV). In the entire group of patients with 
endometrial cancer, no relationship was detected between 
intensity of NESF-1 expression and the stage of clinical ad-
Figure 1. Percentage of endometrial cancer cases manifesting a high expression of a given protein in endometrioid and non-endometrioid cancer 
cells;  p < 0.05
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The mean age of the entire patient group studied was 
65.3; in women with endometrioid cancer the mean age was 
64.7 (34–83) and in women with non-endometrioid cancer 
it was 67.6 (40–83) (p > 0.05).
The tissue material was fixed in 10% buffered forma-
lin, pH 7.4 and placed in a processor. The neoplastic tissue 
was embedded in paraffin at 60oC using standard histo-
pathological techniques. The paraffin blocks were sliced in 
a microtome to 4–5 um thick sections, placed on adhesive 
glass slides and left for one hour at a temperature of 60oC. 
In the study, the immunohistochemical method — DAKO 
EnvisionTM Flex+ (Dako system, Dako, Santa Clara, USA) was 
applied. Antigens were detected in the paraffin sections 
using the Target Retrieval Solution, high pH, DAKO in the 
PT-link (Dako, Santa Clara, USA) at a temperature of 97oC, 
for 20 min.
Nesfatin-1 was estimated using Nesfatin-1/Nucleobind-
ing-2 Antibody (Novus Biologicals, Littleton, USA, NBP1-
87383). In order to detect antigens present in the tissue 
material antibodies were used against ARID1A (Novus 
Biological, Littleton, USA, NBP1-88932), Met (Santa Cruz 
Biotechnology, Santa Cruz, USA, clone C-12, MLH1 (Leica 
NCL-L, Buffalo Grove, USA. Clone E-305), MSH2 (Invitrogen, 
Carlsbad, USA , clone FE11).
The intensity of NESF-1, ARID1A, c-MET, MLH1, 
MSH2 staining was estimated using a 4-degree scale:
no reaction
+ 1 to 50 immunopositive cells (cell nuclei or the cytoplasm)
++ 50 to 75 immunopositive cells
+++ 75 to 100 immunopositive cells
per 10 visual fields.
A positive reaction was accepted in the case of prepara-
tions manifesting ++ or +++ staining.
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vancement of the disease (p = 0.382). Also no such relation-
ship was detected for MLH1, MSH2, c-MET and ARIDIA.
Grading
Among all the analyzed patients no relation was detect-
ed between the level of NESF-1 expression and histological 
grade of cancer differentiation (p = 0.3145). Furthermore, no 
such relationship was detected for MLH1, MSH2, c-MET and 
ARID1A (p > 0.05) (Fig. 2, 3). The group of patients with type 
I EC with grade 1 manifested a statistically higher expression 
of nesfatin than the patients with histologically less mature 
cancer (G1 68.97% vs G2 + G3 45.45%, p = 0.0487). The re-
lationship between the level of studied protein expression 
and histological grading of non-endometrioid cancers was 
not analyzed since the latter by definition are poorly dif-
ferentiated cancers (G3).
Correlation between evaluated proteins
Among all the studied patients with ECs, a high expres-
sion of NESF-1 correlated with a high expression of the 
MLH1 protein (p = 0.039). No relationship was detected 
between the level of NESF-1 expression and MSH2, c-MET 
and ARID1A in the entire population of patients with endo-
metrial cancer (p = 0.43, p = 0.24, p = 0.4158).
DISCUSSION
NESF-1, the amino acid derivative of NUCB2 carries 
prognostic significance in type I EC; its immunoreactiv-
Figure 2. Percentage of endometrial cancer cases manifesting a high expression of a given protein in relation to the clinical stage
Figure 3. Percentage of endometrial cancer cases in the entire population of patients manifesting high expression of a given protein in relation to 
histopathological grading
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ity correlated with an augmented risk of relapse and poor 
clinical course [23]. In the presented study, two groups of 
patients were analysed — women with endometrial can-
cer endometrioid type (EC I) and non-endometrioid (EC II). 
The expression of NESF-1 was more pronounced in type II 
EC (61.3%) with a poorer prognosis compared to type I EC 
(NESF-1 expression in 50.9% cells). However, no statistically 
significant values were determined (p = 0.410). The evalua-
tion of expression in various grades of histological grading 
determined that patients with type I EC at G1 manifested 
a higher expression of NESF-1 than those with type I EC 
at both G2 and G3 (G1 — 68.97% compared to G2 and 
G3 — 50.4%, p = 0.0487). Similar results were observed in 
studies of Takagi et al. [23] in type I EC, though no statistical 
significance was identified (in G1 cancers the proportion of 
positive reaction was higher than in G2 and G3).
Mutations in MLH1 and MSH2 linked with Lynch syn-
drome carry a risk of developing type I EC. In the group of 
patients presented in this study, the expression of MLH1 pro-
tein was significantly higher in type II EC. Among all 146 pa-
tients, a high expression of NESF-1 correlated with a high ex-
pression of MLH1 (p = 0.039), which seems to be slightly con-
troversial. In the literature, a high expression of NESF-1 was 
linked to poorer prognosis, while MLH1, associated with 
type I EC, was linked to better prognosis [2, 23, 24]. Dividing 
the patients according to the histological type of the tumor, 
a tendency was noted for a high expression of NESF-1 in 
patients with a high expression of MSH2 (p = 0.0596). This 
might indicate that despite the normal function of the MMR 
protein group, a high expression of NESF-1 is significant for 
prognosis in the patient group. 
c-Met, also called tyrosine-protein kinase Met, is pro-
to-oncogene tyrosine kinase, located on chromosome 
7q21-31. Physiologically, it is essential for the disruption of 
cadherin-based cell–cell contacts and subsequent cell motil-
ity which takes place is embryonic development, organo-
genesis and wound healing [25]. It activates a wide range 
of different cellular signalling pathways, including those 
involved in proliferation, motility, migration and invasion. In 
many human primary tumours, amplification of the c-MET 
gene, with consequent protein overexpression and kinase 
activation, has been found. In our study, the expression of 
c-MET was most pronounced among the studied param-
eters: it was noted in over 80% of all tissues in both type 
I and type II ECs. No relationship was detected between the 
expression of c-MET and clinical stage or grading, although 
in the literature there is a correlation between its expression 
and metastatic disease and poor prognosis [26, 27].
ARID1A is located on chromosome 1p36.11 and encodes 
protein ARID1A, an important member of the SWI/SNF com-
plex. This complex is responsible for chromatin remodelling, 
which regulates gene expression depending on changes 
in chromatin structures, and participates in replication, 
transcription and repair processes [28]. Dysfunction in the 
mechanism leads to carcinogenesis mainly via PI3K/AKT 
pathway. Mutations in ARID1A are found in many cancers 
and are common in gynaecological cancers such as clear 
cell and endometrioid ovarian cancer, but also in around 
40% of endometrioid EC [29–31]. In our material, expres-
sion of ARID1A protein was detected in around 48% of all 
EC patients. 
No differences in the expression of ARID1A protein were 
revealed in our study between clinical stages and histo-
logical grades. No relationship was also detected between 
ARID1A expression and the studied proteins (NESF-1, MLH1, 
MSH2, c-MET). 
In both subgroups of patients, no other relationships 
were detected between the levels of expression of NESF, 
MLH1, MSH2, c-MET and AR1D1A. 
CONCLUSIONS
In this study on protein expression, EC tissues mani-
fested (although insignificantly) an elevated expression 
of NESF-1 in type II EC. In type I EC, NESF-1 expression was 
significantly higher in G1 in comparison to G2 and G3 com-
bined. A significantly lower expression of MLH1 was dem-
onstrated in type I EC. The most pronounced expression 
involved c-MET in all EC I and EC II tissues (in over 80% of 
cases). A tendency was detected for a high expression of 
NESF-1 in patients with type II EC, who also exhibited a high 
expression of MSH2. 
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